Sofie Eg Jørgensen
Assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Chronic granulomatous disease (CGD) is a severe inborn error of immunity caused by NADPH oxidase defects. Here, we develop CRISPR/Cas9-based gene editing strategies for correction of variants in the CYBA and CYBB genes causing CGD. For X-linked CGD, we also develop a near-universal gene editing strategy by targeted integration of a truncated CYBB cDNA in CD34 + hematopoietic stem and progenitor cells (HSPCs). Throughout, off-target editing and chromosomal translocations are evident, which negatively impact the ability of gene-edited HSPCs to engraft in immunodeficient mice. However, by employing a high-fidelity Cas9 to minimize off-target editing, we demonstrate restoration of the multilineage engraftment potential of gene-edited HSPCs. Moreover, to further improve safety, we develop a D10A Cas9n editing approach with no detectable off-target activity or chromosomal translocations. Collectively, through risk assessments of different gene editing approaches, we present a D10A Cas9n-based strategy with improved safety, offering a potentially curative treatment for CGD patients.
Year:
2025
Year:
2025
Long COVID represents a significant global health challenge with an unclear etiology. Alongside accumulating evidence of mitochondrial dysfunction in patients with acute SARS‐CoV‐2 infection, a symptomatic overlap exists between long COVID and mitochondrial disorders. However, the genetic underpinnings of mitochondrial dysfunction in long COVID have not been previously explored. We employed whole genome sequencing to analyze 13 patients with severe long COVID to identify genetic defects related to mitochondrial function. We performed extracellular bioenergetics flux analysis on peripheral blood mononuclear cells and proteomics to evaluate cellular bioenergetics and compared the results to those of healthy controls. Our investigation identified 10 variants classified as pathogenic or likely pathogenic and 83 variants of unknown significance affecting a wide range of mitochondria‐associated biological functions. Bioenergetics flux analysis in peripheral blood mononuclear cells revealed an altered ATP production rate in four long COVID patients compared to healthy controls. This study presents initial evidence of a potential underlying genetic predisposition to mitochondrial dysfunction in long COVID while demonstrating altered cellular energy capacity in a subset of these patients. These findings open avenues for further research into the role of mitochondrial dysfunction and pathology in patients suffering from long COVID and may pave the way for targeted therapeutic strategies aimed at mitigating mitochondrial dysfunction.
Year:
2025
Background Type I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared across different ARDS etiologies, and the potential effect of dexamethasone (DXM) on these mediators is not known. Methods We assessed the integrity of the alveolo-capillary membrane, interleukins, type I, II, and III IFNs, and IFN autoantibodies by studying the epithelial lining fluid (ELF) volumes, alveolar concentration of protein, and ELF-corrected concentrations of cytokines in two patient subgroups and controls. Results A total of 16 patients with CARDS (four without and 12 with DXM treatment), eight with non-CARDS, and 15 healthy controls were included. The highest ELF volumes and protein levels were observed in CARDS. Systemic and ELF-corrected alveolar concentrations of interleukin (IL)-6 appeared to be particularly low in patients with CARDS receiving DXM, whereas alveolar levels of IL-8 were high regardless of DXM treatment. Alveolar levels of IFNs were similar between CARDS and non-CARDS patients, and IFNα and IFNω autoantibody levels were higher in patients with CARDS and non-CARDS than in healthy controls. Conclusions Patients with CARDS exhibited greater alveolo-capillary barrier disruption with compartmentalization of IL-8, regardless of DXM treatment, whereas systemic and alveolar levels of IL-6 were lower in the DXM-treated subgroup. IFN-I autoantibodies were higher in the BALF of CARDS patients, independent of DXM, whereas IFN autoantibodies in plasma were similar to those in controls.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (24)
Elisabeth Bendstrup
VIP, Clinical Professor
Aarhus University
Anne Louise Schacht Revenfeld
Aarhus University
Søren Sperling
Aarhus University
Ronan Berg
Københavns Universitet
Jacob Giehm Mikkelsen
VIP, Professor
Aarhus University
Kristoffer Skaalum Hansen
Aarhus University
Steffen Leth
Associate Professor
Aarhus University
Thomas Holm Pedersen
Associate Professor
Aarhus University
Hans Erik Bøtker
Professor
Aarhus University
Johan Palmfeldt
VIP, Associate Professor
Aarhus University
Rasmus Bak
VIP, Associate Professor
Aarhus University
Morten Kelder Skouboe
Aarhus University
Christina Ringmann Fagerberg
Clinical Associate Professor
University of Southern Denmark
Jonas Wolff
Aarhus University
Sean Knight
The University of Manchester
Tracy Hussell
The University of Manchester
Jane Agergaard
Aarhus University Hospital
Andreas Fløe
VIP, Clinical Associate Professor
Aarhus University
Martin Thomsen
VIP, Associate Professor
Aarhus University
Lars Østergaard
Professor
Aarhus University
Trine Hyrup Mogensen
DVIP-external, Professor
Aarhus University
Berit Schiøttz Christensen
Professor
University of Southern Denmark
Eva Kildall Hejbøl
Assistant Professor
University of Southern Denmark
Madhvi Menon
The University of Manchester
Make your next move.
Prepare your application
Review drafts before you send them.